Ajanta Pharma Q1 Results Reported Total Income of ₹1,171.39 Crore and PAT of ₹245.77 Crore

Ajanta Pharma Q1 Results 2024-2025: Ajanta Pharma declared its Q1 results on 14 August 2024, showing a strong performance with a 7.5% increase in revenue year-over-year (YoY). The company's total income for the quarter stood at ₹1,171.39 crore, up from ₹1,089.58 crore in the previous quarter (QoQ).

This rise was mainly driven by higher sales in the emerging markets of Asia and Africa, as well as steady growth in the U.S. generics business. The company also posted a profit after tax of ₹245.77 crore, marking a 21.2% rise compared to Q1 of the previous year.

On a quarter-over-quarter (QoQ) basis, Ajanta Pharma saw a 15.8% improvement in profit before tax, reaching ₹322.12 crore from ₹278.04 crore in Q4 of FY 2023-2024. Expenses remained under control, with total expenses increasing only slightly by 4.6% QoQ to ₹849.27 crore.

Employee benefits also rose by 21.5% YoY, highlighting the company's investment in talent. Earnings per share (EPS) improved to ₹19.54, up from ₹16.10 in the previous quarter, showcasing solid profitability for the company in Q1.

For More Q1 results check our Twitter Page

Ajanta Pharma Q1 Results 2024 - 2025

Ajanta Pharma has released its Q1 results for the financial year 2024-2025, showcasing steady growth in revenue and profit. The company's focus on expanding in international markets and maintaining operational efficiency has led to a notable improvement in key financial metrics.

Below is a summary of the important figures from the Q1 results:

Source: Click Here

Ajanta Pharma Current Market Overview

Ajanta Pharma is currently trading at ₹3,130 per share, showing a small decline of 0.64%. The company's market value is ₹39,097 crore, and its stock has ranged between a high of ₹3,486 and a low of ₹1,650 in the past year.

With a price-to-earnings (P/E) ratio of 45.8, Ajanta Pharma is considered a strong player in the pharmaceutical industry. It also provides a 1.15% dividend yield to its shareholders. The company's return on capital employed (ROCE) is 31.6%, and its return on equity (ROE) is 23.2%, reflecting good financial health and profitability.

Quarterly Results

Here’s a summary of Ajanta Pharma's financial performance for the last three quarters:

In the recent quarters, Ajanta Pharma has shown notable growth in sales and profitability. The company's operating profit and net profit have increased significantly, reflecting strong financial health.

About Ajanta Pharma 

Ajanta Pharma is an Indian multinational pharmaceutical company, founded in 1973. It develops, manufactures, and markets a wide range of high-quality medicines, serving customers in over 30 countries, including the United States, Africa, and Asia.

The company is known for its focus on branded generics, producing innovative and first-to-market products in various therapeutic segments. Ajanta Pharma operates seven manufacturing facilities in India, approved by regulatory bodies like the US FDA and WHO, ensuring that its medicines are trusted by healthcare professionals and patients globally.

Visit our website for more Q1 results.